Disc Medicine develops therapies for rare blood disorders, leveraging clinical-stage biotech expertise in red blood cell biology.

This clinical-stage biopharmaceutical company recently had one of its treatments rejected for FDA approval. Now the company is cutting its workforce.

A new biotech has taken flight as a result of Novartis’ red-hot $12 billion acquisition of muscular dystrophy specialist Avidity Biosciences. | A new biotech has risen from the ashes of Novartis’ ...

This S&P 500 REIT develops and leases Class A office and lab space to life sciences and technology tenants in top U.S.

A new, highly sensitive cell therapy was able to wipe out three different kinds of solid tumors in mice, an important advance in an area where CAR-T cells have long struggled. But significant ...

Indian vaccine developer Bharat Biotech International Ltd. is considering an initial public offering that may raise more than ...

HealthDay News — Ultra-endurance running accelerates red blood cell (RBC) aging through inflammatory and oxidative pathways, according to a study published online Feb. 18 in Blood Red Cells & Iron.

Marty Makary appeared for Thursday an interview on CNBC to tout efforts under his leadership at the Food and Drug Administration to speed up approvals for treatments of rare diseases. Instead, he ...

Former Pentagon advisor expands the firm’s work on national security, dual-use technology, and regulatory risk facing ...

A Senate hearing probed whether the Food and Drug Administration's process for approving rare-disease therapies is ...

Canada’s Globe and Mail — widely regarded as Canada’s most influential national publication —sent a reporter to the Deep South to figure out how Alabama had become richer than their country. The ...